Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott F Huntington

Showing results (21-30 of 81) with videos related to

Pageof 9
Sort By:
Future Oncology (London, England)|December 5, 2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphomaMahek Garg, Justin Puckett, Sachin Kamal-Bahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 3, 2024
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory SettingMahek Garg, Justin Puckett, Sachin Kamal-Bahl, et al.
Expert Review of Hematology|June 5, 2019
Healthcare expenses for treatment of acute myeloid leukemiaJan Philipp Bewersdorf, Rory M Shallis, Rong Wang, et al.
Leukemia & Lymphoma|July 27, 2023
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costsPatrick Squires, Justin Puckett, Katherine Elizabeth Ryland, et al.
JNCI Cancer Spectrum|August 8, 2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomasMengyang Di, Kunal C Potnis, Jessica B Long, et al.
Cancer|June 23, 2017
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantationLucy Hui, Gottfried von Keudell, Rong Wang, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
British Journal of Haematology|June 19, 2015
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cellsAndrew G Evans, Paul G Rothberg, W Richard Burack, et al.
Leukemia & Lymphoma|September 21, 2023
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaScott F Huntington, Beenish S Manzoor, Justin T Puckett, et al.
Blood Advances|November 7, 2022
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphomaKunal C Potnis, Mengyang Di, Iris Isufi, et al.
Pageof 9

Showing results (21-30 of 81) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|December 5, 2023
Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphomaMahek Garg, Justin Puckett, Sachin Kamal-Bahl, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 3, 2024
Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory SettingMahek Garg, Justin Puckett, Sachin Kamal-Bahl, et al.
Expert Review of Hematology|June 5, 2019
Healthcare expenses for treatment of acute myeloid leukemiaJan Philipp Bewersdorf, Rory M Shallis, Rong Wang, et al.
Leukemia & Lymphoma|July 27, 2023
Assessing unmet need among elderly Medicare Beneficiaries with Mantle cell lymphoma: an analysis of treatment patterns, survival, healthcare resource utilization, and costsPatrick Squires, Justin Puckett, Katherine Elizabeth Ryland, et al.
JNCI Cancer Spectrum|August 8, 2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomasMengyang Di, Kunal C Potnis, Jessica B Long, et al.
Cancer|June 23, 2017
Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantationLucy Hui, Gottfried von Keudell, Rong Wang, et al.
Journal of Managed Care & Specialty Pharmacy|July 24, 2024
Real-world comparison of health care costs of venetoclax-obinutuzumab vs Bruton's tyrosine kinase inhibitor use among US Medicare beneficiaries with chronic lymphocytic leukemia in the frontline settingScott F Huntington, Beenish S Manzoor, Dureshahwar Jawaid, et al.
British Journal of Haematology|June 19, 2015
Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cellsAndrew G Evans, Paul G Rothberg, W Richard Burack, et al.
Leukemia & Lymphoma|September 21, 2023
Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemiaScott F Huntington, Beenish S Manzoor, Justin T Puckett, et al.
Blood Advances|November 7, 2022
Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphomaKunal C Potnis, Mengyang Di, Iris Isufi, et al.
Pageof 9